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RODUCTION 
SLE is an episodic multisystem autoimmune disease characterised by 
widespread inflammation  of  bloodvessels and  connective tissues  and by 
the presence of antinuclear antibodies especially antibodies to native double 
stranded  DNA. Its clinical manifestations are extremely variable and its 
natural history is unpredictable. Untreated SLE is often progressive and has 
a significant fatality rate.[1]   
It is the second commonest pediatric rheumatic disorder next to 
juvenile idiopathic arthritis. The clinical course can range from mild to 
severe and can be potentially life threatening. [1-5] 
SLE is a relatively rare disease in childhood with estimated incidence 
ranging from 10 to 20 per 1lakh children depending on the ethnic 
population. [1-5] 
Hence the study is undertaken to know about the varied clinical 
presentation, immunological status, disease activity  and damage to organs 
at follow up. 
SYSTEMIC LUPUS ERYTHEMATOSUS 
Lupus  - the  latin  word  for wolf.[1]  Kaposi  in  1872  described the  
skin lesions. Osler described  the  systemic  nature  of  the  illness.SLE  is  
an  episodic, multisystem, autoimmune  disease  characterised by  
widespread  inflammation  of  blood  vessels  and  connective  tissues  and  
by  the  presence  of  antinuclear  antibodies(ANAs).  
 EPIDEMIOLOGY 
Prevalence in asians is three times more than in whites. In afro 
caribbeans it is six times more common than in whites. 15 to 17% of cases 
have onset in childhood. Onset is rare before 5 years and uncommon before 
adolescence. When we take sex ratio girls are more affected than boy but it 
varies with age of onset.[1] 
GENETIC BACKGROUND  
The concordance rate is more in monozygous twins. A connective  
tissue  disorder  other  than  SLE  occurs  in  about 1 in  10 families  of  
patients  with  SLE. There  is  20%  increased  risk  for  SLE  among  first  
degree  relatives. The genes associated   are major histocompatibility 
complex class 2 DR2, DR3 in whites, DR2, DR7 in african-americans, DQ 
alleles major  histocompatility  complex  class III, C2, C3, C4A, null, C1q, 
C1r, C1s, mannose binding protein, tumor necrosis factor-alpha, Fc gamma 
II,and Fc gamma III.[1] 
ETIOLOGY   
Unknown except for drug induced lupus. A number of factors may act 
independently or in concert to trigger onset of the disease. Immune 
dysregulation in the form of hormones like decrease in androgens and 
increase in estrogens, in males and females. FSH, LH and prolactin are also 
elevated. Environmental factors like ultraviolet B, increases 
immunogenicity of DNA and inflammation. Viral infection, elevated titers 
of antiviral antibodies probably reflect polyclonal B cell activation. Drugs 
which are definitely associated are isoniazid, phenytoin, alphamethyldopa, 
chlorpromazine, ethosuximide, hydralazine, procainamide, primidone and 
trimethadione. Drugs probably associated are penicillin, penicillamine, 
carbamazepine, sulphonamides, quinidine, captopril, metoprolol,and 
minocycline. [1] 
CRITERIA FOR CLASSIFICATION  
The AMERICAN COLLEGE OF RHEUMATOLOGY criteria 1982  
modified in 1997. [14-15]  Sensitivity - 96% and specificity-100% in 
childhood lupus.  A child is said to have SLE if any 4 or more of the 11 
criteria are present serially or simultaneously, during any time of 
observation. 
They are malar rash, discoid rash, photosenstivity, oral ulcers, 
arthritis, serositis, renal disorder, neurological disorder, hematological   
disorder, immunologic disorder and antinuclear antibody. 
 CRITERION DEFINITION 
1 Malar  rash Fixed erythema, flat or raised, over the malar 
prominences, tending to spare the nasolabial folds.
             
2 Discoid  rash Erythematous raised patches with adherent 
keratotic, scaling, and follicular  plugging; 
atrophic scarring may occur in older lesions. 
3 Photosensitivity Skin rash as a result of unusual reaction to  sunlight 
 CRITERION DEFINITION 
4 Oral  ulcers Oral/nasopharyngeal ulcers,usually painless 
5 Arthritis Nonerosive arthritis involving 2 or more 
peripheral joints. 
6 Serositis Pleuritis or pericarditis 
7 Renal disorder Proteinuria of more than 0.5 gm/day or more than 
3+ or cellular casts 
8 Neurological  
disorder 
Seizures or psychosis in the absence of offending 
drugs or known metabolic causes. 
9 Hematological    
disorder 
Hemolytic anemia with reticulocytosis or 
leukopenia < 4000/mm3 on 2 or more  occasions or 
lymphopenia < 1500/mm3 on 2 or more occasions 
or thrombocytopenia  
< 1,00,000/mm3 on 2 or more occasions 
10 Immunological Positive LE cell preparation or Anti DNA  
 CRITERION DEFINITION 
disorder antibody or presence of  anti Sm antigen or  false 
positive serological test for syphilis                         
positive for at least 6 months and  confirmed by 
TPI/FTA-ABS 
11 Antinuclear 
antibody 
An abnormal titre of ANA by antibody immuno 
fluorescence or equivalent assay at any point in 
time and in the absence of drugs known to cause 
lupus.                   
CLINICAL MANIFESTATIONS      
SLE can present as an insidious, chronic illness, an acute, or a rapidly 
fatal disease. Constitutional symptoms are common at onset and during 
exacerbations. 
CUTANEOUS MANIFESTATIONS: [16] 
Classic butterfly rash is seen in 1/3rd to 1/2nd of cases. This lesion  is  
not  pathgnomonic of SLE. It is  symmetric, sparing the nasolabial folds, 
slightly raised and well demarcated lesion unlike in JDM which is usually 
less well demarcated and photosensitive. It is usually non scarring.  
Discoid rash is rarely seen in children. It is an erythematous, circular, 
raised patch which heals with scarring. 
Other lesions include maculopapular rashes, petechiae and palpable 
purpura due to vasculitis, periungual erythema, gangrene, nailchanges, 
alopecia, subacute lupus, bullous lesions, discoid lupus, photosensitivity, 
urticarial  leukocytoclastic  vasculitis, etc. 
MUCOSAL INVOLVEMENT 
Classic lesion is a painless, shallow, ragged ulcer on the hard palate. It 
is uncommon. Ulceration or perforation of nasal septum, aphthous stomatitis 
are common.  
ARTHRITIS  
Arthritis of small joints usually lasts for 24 to 48 hours. Pain is severe 
than objective findings, non erosive and can be migratory. Myalgia or 
proximal muscle weakness is usually prominent. 
LUPUS NEPHRITIS: [17-19] 
Lupus nephritis is a major determinant of long term outcome. Occurs 
in about 75% of children. Disease is more frequent and of greater severity in 
children than in adults. 
 HISTOLOGY MANIFESTATION 
Class    
I 
Normal No detectable disease 
Class  
II A 
II B 
Minimal  change 
disease 
Mesangial  
glomerulitis 
 
Minimal  proteinuria  or 
Hematuria 
Class  
III 
Focal and  
segmental  
proliferation 
Proteinuria or hematuria, usually does not 
progress  to  renal  failure 
 HISTOLOGY MANIFESTATION 
Class  
IV 
Diffuse 
proliferative  
glomerulo  
nephritis 
Nephrotic syndrome  and renal insufficiency 
in 60% 
Class  
V 
Membranous 
glomerulo nephritis
Persistent nephrotic  syndrome, hypertension 
in 30%, renal failure in  majority 
Class   
VI 
Glomerular 
Sclerosis 
Segmental or extreme sclerosis of 
glomerulus. Fibrous crescents are common 
NEUROPSYCHIATRIC MANIFESTATIONS 
Neuropsychiatric manifestations rank second only to nephritis. It 
occurs in 20 to 40% of cases. 
Psychiatric manifestations include depression (most common), 
suicidal tendencies, visual, tactile hallucinations and emotional lability.  
Neurological manifestations include headache, seizures, movement 
disorders like chorea, ataxia, tremor, hemiballismus, cerebrovascular 
accidents, cranial and peripheral neuropathy, papilledema, visual loss, 
vertigo, myelopathy, and cognitive impairment. 
CARDIAC MANIFESTATIONS 
  Pericarditis is most commonly seen in 30% of cases, myocarditis in 
10 to 15% of cases, accelerated atherosclerosis and myocardial infarction in 
long standing cases. The classic lesion is Libman-Sacks endocarditis, which 
is less common and often subclinical.  
VASCULAR DISEASE 
Vasculitis affects small blood vessels-arterioles and venules. 
Raynaud’s phenomenon, livedo reticularis, thrombosis, erythromelagia, 
lupus profundus may occur. Lupus crisis is the sudden development of 
overwhelming, often fatal, systemic disease due to widespread acute 
vasculitis. 
PLEURO PULMONARY DISEASE 
Subclinical disease is common in children. Pleuritis, basilar 
pneumonitis, pneumothorax, atelectasis, pulmonaryhemorrhage, shrinking 
lung (diaphragmatic dysfunction), acute lupus pneumonitis, infections, and 
interstitial lung disease. 
HEMATOLOGICAL MANIFESTATIONS 
 Hemolytic anemia with reticulocytosis or leukopenia  < 4000/mm3 on 
2 or more occasions or lymphopenia < 1500/mm3 on 2 or more occasions or  
thrombocytopenia < 1,00,000/mm3 on 2 or more occasions in the absence of  
offending drugs. Anemia - most common, usually normocytic, 
normochromic. Coomb’s test is positive in 30 to 40%, less than 10% have 
overt hemolysis. 
IMMUNOLOGIC DISORDER [20] 
 Positive  LE  cell  preparation  or  Anti  DNA  antibody  or  presence  
of  anti  Sm  antigen  or  false  positive  serological  test  for  syphilis  
positive  for  at least 6  months  and     confirmed  by  TPI  or  FTA-ABS.                       
ANTINUCLEAR ANTIBODY 
An abnormal titre of ANA  by  immuno fluorescence  or  equivalent  
assay  at  any  point  in  time  and  in  the  absence                                 of  
drugs known to cause lupus.   
ANTIBODIES PREVALENCE SIGNIFICANCE 
Antinuclear 
antibodies  
98% Best  screening test 
Anti  ds  DNA 70% SLE specific; titres correlate  with  
disease  activity  in  some. 
Anti  Sm 25% SLE  specific 
Anti  RNP 40% Seen  in  overlap  syndromes. 
Anti  Ro (SS-A) 30% Not SLE specific; associated with 
sicca syndrome, neonatal lupus, 
subacute cutaneous lupus, 
decreased risk of nephritis. 
Anti  La (SS-B) 10% Decreased risk of nephritis. 
Antihistone 70% Drug induced lupus. 
Antiphospholipid 50% Coagulation disorders. 
Antierythrocyte 60% Measured as direct Coomb’s test. 
Antiplatelet 30% Thrombocytopenia. 
ANTIBODIES PREVALENCE SIGNIFICANCE 
Antineuronal 60% Active CNS lupus. 
Antiribosomal  P 20% Correlates with depression or 
psychosis. 
GASTROINTESTINAL DISEASE   
Peritonitis, vasculitis, pancreatitis, colitis, malabsorption, esophageal 
dysfunction, pseudo-obstruction, paralytic ileus, hepatosplenomegaly, 
perisplenitis, and functional asplenia may occur. 
OCULAR DISEASE 
Cotton wool spots, subretinal edema/ hemorrhage, CRV occlusion, 
episcleritis, papilloedema, retinopathy. 
SECONDARY SJOGREN’S SYNDROME 
Keratoconjunctivitis sicca and xerostomia. 
ENDOCRINOPATHIES 
 Autoimmune thyroid disease - hypo and hyperthyroidism, steroid  
induced diabetes mellitus, delayed puberty and  menstrual  abnormalities.  
APPROACH TO MANAGEMENT OF SLE[1] 
Counselling, education,team approach 
Adequate rest, appropriate nutrition 
Use of sunscreen 
Immunisation,especially antipneumococcal vaccine 
Prompt management of infection 
Non steroidal anti inflammatory drugs 
For musculoskeletal signs and symptoms 
Anticoagulation 
If anticardiolipin antibodies are present in high titres,  
lowdose aspirin is used. 
Heparin, followed by warfarin if thrombosis has occurred 
Hydroxychloroquine 
For cutaneous disease and as an adjunct to glucocorticoids    
for systemic disease 
Glucocorticoids 
Oral prednisolone 1-2 mg/kg/day 
IV methyl prednisolone initially and at monthly intervals for  
maintenance therapy in severe disease 
Immunosuppressives 
Azathioprine 1-2 mg/kg/day(PO) 
Cyclophosphamide 1-2 mg/kg/day(PO) or 
500-1000 mg/m2/mo  IV in severe disease 
AIM OF THE STUDY 
1. To study the clinical profile of SLE among children less than 12 
years attending an urban referral hospital. 
2. SLEDAI scoring at onset and follow up at 1 year. 
3. SLICC/ACR-DAMAGE INDEX at 1 year 
     REVIEW OF LITERATURE 
1. Surjit singh et al. studied  the  clinical  and  immunological  profile 
of children with SLE at the Dept. of Pediatrics, PGIMER, Chandigarh. [6] 
They studied 16 cases in the age group 4-12 years. Mean age of children at 
the time of diagnosis was 10 yr. Female to male ratio was 7:1. Fever, rash, 
arthritis were common presentation. Renal involvement was noted in 56.2%. 
ANA positivity is seen in all children. 5 had cardiac involvement and 3 had 
renal involvement. They concluded SLE must be considered in any child 
with multisystem disease. [6] 
2. L.B.Tucker, division of pediatric rheumatology, British                   
Columbia children hospital, vancouver, BC, canada Lupus(2007)16 546-  
549.In this article classification criteria for SLE are discussed and an 
approach to making an accurate and timely diagnosis is considered.[7] 
3. FR Pluchinotta et al. Dept of pediatrics rheumatology, university of 
padova Italy Lupus 2007:16;550 conducted this study with pediatric SLE  
with onset in infancy, prepubertal and postpubertal age.[8] Postpubertal 
patients show higher frequency of musculoskeletal involvement and 
leucopenia, strong female preponderance and more specific signs of disease. 
Serological status was not significantly different in the three groups. 
Prevalence of internal organ involvement seems to decrease with age. 
Prepubertal patients have an intermediate disease severity and no gender 
predilection. Infantile SLE showed a significantly higher prevalence of 
cardiovascular and  pulmonary involvement, anemia and  thrombocytopenia 
and shorter disease duration at time of diagnosis.                                                             
4. Damage did not independently influence mortality in childhood 
SLE.  Simone Appenzeller.Roberto Marini.Rheumatol Int (2005)25:619-
624.In this study 61 patients identified. Six were lost to follow up. Mean 
SLICC/ACR DI  Score was 4.9.Death  occurred  in  12  of  55  patients. 
Male gender, the  presence  of  infection  and  nephritis  were  independent   
risk  factors  for  death. Damage  did not  influence  survival  in  this  
study.[ 9] 
5. Clinical Features and Outcome of Systemic Lupus Erythematosus. 
Indira Agarwal, T Sathish Kumar, Kala Ranjini, Chellam Kirubakaran et al 
reported the clinical profile,treatment and outcome of systemic lupus 
erythematosus in 70 patients  between the ages of 4-15 years at Christian 
medical college Vellore,India. Fever,arthritis and rash were extrarenal 
manifestations. Anemia was seen in 60% and direct Coombs test was 
positive in 58.3%. Antinuclear antibody was positive in all; anti-double 
stranded DNA antibody and low C3 levels were seen in 77.1% and 80%, 
respectively. Renal involvement was noted in 77.1% and included 
proteinuria (53%), hematuria (42.8%), hypertension (18.5%) and elevated 
serum creatinine (8.6%). Renal histology showed class I nephritis in 3.7%, 
class II in 44.4%, class III in 4.3%, class IV in 44.4% and class V in 1.8%. 
On follow up 18.8 months later, 70% patients were in remission, 7.5% had 
active disease and 7.5% died. The characteristics of childhood lupus 
erytematosus were similar to those previously reported. The outcome was 
favourable in most cases.[34] 
6. A. N. Chandrasekaran et al  studied 330 adult Systemic Lupus 
Erythematosus (SLE) cases who attended the Rheumatic Care Centre, 
Government General Hospital,Chennai. 59 children were analysed. There 
was no case with onset before the age of 5 years. There were 49 females and 
10 males (M:F =1:4.9). The initial manifestations were fever (67%), arthritis 
(61%), skin rash (59%) and lymphadenopathy (27.1%). There was no case 
of Raynaud's phenomenon. Only 10.1% of patients presented with 
thrombocytopenic purpura. In the cumulative clinical features, arthritis in 
86.6%, fever in 79.8%, skin rash in 69.4%, lymphadenopathy in 61% and 
hepatosplenomegaly in 39.9% were observed. Renal involvement was seen 
in 49.1%, neuropsychiatric manifestations in 27.1%, pleuropulmonary in 
22% and cardiac manifestations in 10.2%. Anemia was seen in 50.8%, 
leukopenia in 18.4%, thrombocytopenia in 11.8%, ANA in 100%, anti-
dsDNA in 92.3%, anti-Sm in 34.7%, anti-SSA in 38.5%, anti-SSB in 15.4%, 
ACL in 30.8%, low C3 in 50% and false positive VDRL in 3.3%. Death 
occurred in 8 children, 3 due to infection, 2 due to renal causes, I due to 
cardiac and 2 due to central nervous system involvement. [21] 
7. Severe clinical course of systemic lupus erythematosus in the first 
year of life was done at the university of Padua,Italy.The conclusions drawn 
were, SLE very rarely occured before the age of 5years. The  clinical and 
laboratory characteristics of iSLE patients followed at the Department of 
Pediatrics of Padua were analyzed. A total of 13 patients with iSLE,were  
included . Seven (53.8%) were females and 6 were males (46.2%). The age 
at disease onset ranged from 6 weeks to 11 months. In comparison with 
juvenile systemic lupus erythematosus , iSLE showed a higher prevalence of 
positive family history for autoimmune diseases, systemic symptoms at 
presentation, internal organs involvement, and shorter time between 
symptoms onset and diagnosis. Anemia and thrombocytopenia were present 
in the majority of the patients at diagnosis, whereas leukopenia was rarely 
observed. The overall prognosis in iSLE was very poor: 5/13 infants died 
between 2 and 31 months after the onset, and 5/13 had severe disease course 
with residual organ damage. SLE can start as early as during the first year of 
life and is more severe than in the later age groups.[35] 
MATERIALS AND METHODS 
METHODOLOGY 
Study design - Descriptive/prospective observational study 
Study place - Rheumatology clinic, nephrology ward, medical 
wards of ICH & HC 
Study period - Nov 2007 to Aug 2009. 
Study population - All children diagnosed to have SLE. 
Sample size - 50 
INCLUSION CRITERIA 
 All children < 12 years diagnosed to have SLE. 
EXCLUSION CRITERIA 
         Nil 
MANOEUVRE 
This study was conducted in medical ward,  nephrology  ward, 
rheumatology OPD, in ICH&HC. Clinical features, laboratory 
investigations, treatment were followed for all the children. SLE disease 
activity index and SLICC/ACR damage index was done at diagnosis,  and  
followup   at  1year.Children were divided into three groups based on the 
age of onset as less than 2 years, between 2-10 years and 10-12 years. 
Clinical features, laboratory investigations and treatment were compared 
between the groups. 
STATISTICAL ANALYSIS 
The sample size of the study was 50. Frequency of occurrence of 
clinical, laboratory, and treatment parameters were derived for all the 50 
children. SLEDAI and SLICC/ACR damage index scores had their mean 
values computed. SLEDAI scores were compared between onset and follow 
up by One way ANOVA, Fischer test and P values derived. Analysis 
between three groups of disease occurrence was done by Chi square test and 
p values obtained. p values less than 0.05 is taken as significant. 
RESULTS AND ANALYSIS 
TABLE-1  
 MEAN STANDARD DEVIATION 
AGE AT ONSET OF DISEASE 7.94     
YEARS 
2.92   YEARS 
AGE OF PATIENT 9.46     
YEARS 
2.69   YEARS 
DURATION OF ILLNESS AT 
DIAGNOSIS 
11.06  MO 6.48    MO 
Age at onset of disease was 7.94 years (S.D 2.92) 
Mean age of patients was 9.46 years ( S.D2.69).  
 Duration of illness in patients prior to diagnosis was 11.06 months. 
(S.D 6.48)  
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TABLE -8 
ORGAN INVOLVEMENT-CVS, RS, GIT, CNS 
ORGAN INVOLVEMENT N =50 % 
HEPATOSPLENOMEGALY 35 70 
SEROSITIS 19 38 
SEIZURES 13 26 
CARDIOVASCULAR  4 8 
In GIT involvement 35 cases (70%) had hepatosplenomegaly. 
Serositis  was noted in 19 cases(38%). CNS involvement in the form of 
seizures was noted in 13 cases (26%).Cardiac involvement in the form of 
valvular lesions was found in 4 patients (8%). 
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TABLE 17:  CHARACTERISTICS OF THREE GROUPS 
 
GROUP 
A 
N =5 
GROUP  
B 
N =26 
GROUP C 
N = 19 
      P  
  VALUE 
F:M 5:0 3.3:1 1.7:1 NS 
MEAN DURATION  
AT DIAGNOSIS 
3.8 9.2 15.15 P<0.01 
F: M ratio was 5:0 in Group A, 3.3:1 in Group B, and 1.7:1 in Group 
C. p value was not  significant. Mean duration of illness at diagnosis in 
months was 3.8 in Group A,9.2  in Group B and15.15 in Group C.                    
TABLE: 18 ORGAN INVOLVEMENT-MUCOCUTANEOUS 
 
GROUPA
GROUP  
B 
GROUP 
 C P 
VALUE 
N=5 % N=26 % N=19 % 
MALAR RASH 4 80 17 65.4 15 78.9 0.55 
PHOTOSENTIVITY 2 40 13 50 11 57.9 0.74 
ORAL ULCERS 2 40 21 80.8 11 57.9 0.01 
ALOPECIA 1 20 8 30.8 4 21.1 0.09 
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TABLE 21  OTHER  SYSTEM  INVOLVEMENT 
 
GROUPA GROUP B GROUP C 
P VALUE
N=5 % N=26 % N=19 % 
CVS- VALVULAR 1 20 1 3.8 2 10.5 0.13 
RS – SEROSITIS 4 80 6 23.1 9 47.36 0.01 S 
GIT  -   HEPATO 
SPLENOMEGALY 
5 100 18 69.2 12 63.2 0.27 
CNS – SEIZURES 0 0 8 30.8 5 26.31 0.31 
HEMOLYTIC ANEMIA 3 60 4 15.4 2 10.5 0.03 S 
LEUKOPENIA 0 0 1 3.8 2 10.5 0.54 
THROMBOCYTOPENIA 3 60 6 23.1 6 31.6 0.25 
FEVER 5 100 24 92.3 18 94.7 0.8 
In SLE, CVS involvement in the form of valvular lesions was found in 
1patient (20%) in Group A, 1 patient in Group B (3.8%) and 2 patient 
(10.5%) in Group C. p value was 0.13. 
RS involvement in the form of serositis was found in 4 cases (80%) in 
Group A, 6 cases (23.1%) in Group B and 9 cases (47.36%) in Group C, p 
value was 0.01 which is significant. 
GIT involvement in the form of hepatosplenomegaly was found in 5 
cases (100%) in Group A, 18 cases (69.2%) in Group B, and 12 cases 
(63.2%) in Group C. p value was 0.27. 
CNS involvement in the form of seizures was found only in 8 cases (30.8%) 
in Group B and 5 cases (26.31%) in Group C. p value was 0.31. 
3 cases (60%) in Group A, 4 cases (15.4%) in Group B and 2 cases 
(10.5%) in Group C had hemolytic anemia. p value was 0.03 which is 
significant. 
Thrombocytopenia was noticed in 3 cases (60%) in Group A, 6 cases 
(23.1%) in Group B and 6 cases (31.6%) in Group C. 
Fever was noticed in all cases (100%) in Group A, 24 (92.3%) cases in 
Group B and 18 cases (94.7%) in Group C. p value was 0.8  
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TABLE:  23 
TREATMENT 
 
GROUP 
A 
GROUP 
B 
GROUP 
C P 
VALUE 
N % N % N % 
PREDNISOLONE 5 100 26 100 19 100 - 
METHYL PREDNISOLONE 0 0 8 30.8 6 31.6 0.84 
AZATHIOPRINE 1 20 5 19.2 6 31.6 0.51 
CYCLOPHOSPHAMIDE 2 40 4 15.3 5 26.3 0.3 
MMF 0 0 3 11.5 4 21 0.14 
HYDROXY 
CHLOROQUINE 
1 20 7 26.9 7 36.8 0.62 
Prednisolone was used in all cases (100%).Methyl prednisolone was 
used in 8 cases (30.8%) in Group B and 6cases (31.6%) in Group C. 
Azathioprine was used in 1 case (20%) in Group A, 5 cases (19.2%) in 
Group B, and 6 cases (31.6%) in Group C. p value was 0.51. 
Cyclophosphamide was used in 2 cases (40%) in Group A, 4 cases 
(15.3%) in Group B and 5 cases (26.3%) in Group C. p value was 0.3. 
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DISCUSSION               
In our study there were 50 cases over the last 2 years. Majority of the 
children were diagnosed within a year of their initial manifestation. The 
mean duration of illness prior to diagnosis was 11.06 months in our study. 
The mean age at the time of onset of symptoms was 7.94 years which is 
lowest among other pediatric SLE studies from India and abroad [6,21,22 ]. 
Female to male ratio in our study is 2.5:1 which is comparable with other 
studies. Family history of autoimmunity in first and second degree relatives 
was noted in 8% of patients. 
SLE is a multisystem disorder and the manifestations can be variable. 
In atypical cases the diagnosis may be missed if the suspicion is not high. 
Such children may continue receiving treatment without diagnosis as 
exemplified by some cases. Antituberculosis treatment was received by 3 
cases before diagnosis. One child being treated as pulmonary tuberculosis 
and dilated cardiomyopathy and another child with CNS involvement with 
MRI evidence of demyelination was found to be SLE. Both of them lacked 
the typical mucocutaneous features. 
The most common clinical manifestations were mucocutaneous 
involvement in the form of malar rash, photosensitivity, oral ulcers, and 
alopecia. Discoid rash was rare. Raynauds phenomenon was also not 
noticed. Musculoskeletal involvement in the form of arthritis and 
reticuloendothelial involvement in the form of lymphadenopathy was also 
commonly encountered. This is comparable to other series from India 
[6,21,22  ] and abroad.[20,23,24,25 ]  
Renal involvement was noticed in the form of proteinuria and 
nephrotic syndrome. Among the 8 patients with hypertension, 6 of them had 
renal involvement. Renal biopsy was done in 14 cases out of 20 (70%). 
Majority of patients with lupus nephritis had pathological changes 
consistent with class 3, 4, 5 lesion. One patient with class 3 lesion and one 
patient with class 5 lesion died. 3 patients had peritoneal dialysis and 1 
patient was on CAPD. 
GIT involvement in the form of hepatosplenomegaly was found in 
majority of cases (70%). Serositis in the form of pleural or pericardial 
effusion was noticed in 38% of cases. Cardiovascular manifestations in the 
form of valvular involvement was found in 4 patients (8%). Dilated 
cardiomyopathy, pulmonary hypertension, mitral regurgitation and cardiac 
tamponade were the manifestations seen. The patient with pulmonary 
hypertension had anticardiolipin antibody positive which seems to be a 
manifestation of antiphospholipid antibody syndrome. 
CNS involvement in the form of seizures is found in 13 cases (26%). 
Neuropsychiatric manifestations were found in 2 of these patients. CT scan 
was done in all of these patients. Cerebral atrophy (2no), CVA with multiple 
infarct (2no), Intracerebral bleed (2no), demyelination (1no) were the 
findings. The patient with demyelination had Hodgkins lymphoma. CT scan 
was normal in rest of the patients. 
Fever was noticed in 47 patients. Majority of them presented with 
pyrexia of unknown origin and later found to be SLE. Hemolytic anemia 
was found in 10cases. Thrombocytopenia was found in 30% of cases. 
Leukopenia was found in less no of patients (6%). This is comparable to 
other studies. [6,20,21,22,23,24,25  ]. ANA positivity was seen in 46 cases 
(92%). Anti ds DNA antibody were positive in 52%.Though the value is 
lower when compared with other pediatric series from India, it is in 
accordance with international studies [Tan et al]. The reason was most of 
them were already started on steroids. Hypocomplementemia was noticed in 
80%.This is comparable to other studies. ACL/LAC could not be done in all 
patients. Of the 9 patients  done, 3 showed positivity (34%). 
Prednisolone was used in all cases. Methyl prednisolone was used in 
15 cases (30%) as induction therapy. Azathioprine was used as induction 
therapy in 8%, maintenance therapy in 10% and 6% cases of relapse. 
Cyclophosphamide was used in 22% of cases, majority as induction therapy. 
Children with lupus nephritis received methyl prednisolone and intravenous 
cyclophosphamide 6 monthly pulse doses to induce remission. 
SLEDAI i.e. SLE disease activity index [26 ] was determined at 
diagnosis and at follow up after 1 year. SLEDAI 1 had a mean of 12.54 and 
SLEDAI 2 had a mean of 10.02.This higher score of SLEDAI as compared 
with other studies suggests higher disease activity, diagnosis at later stages 
and poor prognosis [27,28 ]. SLE associated injury was measured by the 
systemic lupus international collaborating clinics/ACR Damage index. 
SLICC/ACR-DI [27,28]. It was evaluated at the end of 1 year. It had a mean 
of 0.68.The lower value as compared with other studies suggest that it 
should be done frequently and requires follow up on long term basis. 
Several studies on pediatric SLE suggest that age at onset modifies the 
expression of the disease in terms of clinical presentation, pattern of organ 
involvement and serological findings[23,30,31,32,33 ]. In our study we 
analysed if SLE has different clinical features in three specific age classes. 
Age less than 2 years constituted 10%, while 2-10years constituted 52% and 
10-12 years 38%. Female to male ratio was 5:0 in group A, 3.3:1 and 1.7:1 
in group B and group C respectively. Age at onset seems to affect clinical 
manifestations and prognosis of SLE. Those who had earlier onset had 
severe disease and worse prognosis. In group A disease duration at 
diagnosis was significantly shorter than the other 2 groups. In older patients 
mean disease duration at diagnosis was higher. 
No significant difference between the groups was observed in the 
family history of autoimmune disorders, mucocutaneous involvement, 
musculoskeletal and reticuloendothelial involvement. Oral ulcers was 
significantly found in group B. This is in confirmity with other studies 
exception being musculoskeletal involvement to be rare in infantile SLE and 
occured with other groups. 
Renal involvement was significantly found in infantile  
SLE. Nephrotic syndrome had no difference. Hypertension was not found in 
infantile SLE, but other groups had no difference. Respiratory system 
involvement occurred significantly in infantile SLE than in other 
groups.GIT involvement was found in all infantile SLE patients. CNS 
involvement was not noticed in infantile SLE, but found in other groups. 
Hemolytic anemia and thrombocytopenia was significantly found in 
infantile SLE. Fever had no difference between the groups. Laboratory 
findings had no difference. 
Treatment with prednisolone, azathioprine, cyclophosphamide, MMF 
and hydroxychloroquine had no difference between the groups. Methyl 
prednisolone was not used in infantile SLE. Cases with lupus nephritis 
received methylprednisolone, cyclophosphamide, MMF to induce remission. 
SLEDAI as index of disease activity had no difference within the 
groups. But the score was high. SLICC/ACR Damage index had no 
difference in the three age classes. Death occurred in 3 cases (6%). Cause of 
death being infection in all. One died due to sepsis, nocardiosis, lupus 
nephritis, another due to drug induced hepatitis and third due to infection. 
SLEDAI score in died patients had significant difference. SLICC/ACR DI 
had significant values with mean of 2.33. 
CLINICAL PRESENTING FEATURES OF CHILDHOOD ONSET 
SLE (NUMBER AND %) 
Characters 
ICH 
present 
study 
Hiraki 
et al 
Rood 
et al 
Font 
et al 
King 
et al 
Casidy 
et al 
No of patients 50 241 31 34 108 58 
Malar rash 72 68 52 44 NR 51 
Arthritis 60 61 74 65 79 72 
Fatigue _ 59 74 NR 33 NR 
Renal disease 40 51 45 20 61 84 
Fever 94 46 68 41 71 NR 
Weight loss _ 34 58 NR 38 NR 
Ulcers 32 29 26 9 NR 12 
Alopecia 26 27 7 NR NR 16 
Serositis 38 15 32/10 12 NR 31/40 
CNS 26 15 10-23 0 13 9 
Headache _ - 36 - 13 - 
Photosensitivity 52 15 16 23 NR 16 
Raynauds 
phenomenon 
0 15 16 12 NR 16 
Characters 
ICH 
present 
study 
Hiraki 
et al 
Rood 
et al 
Font 
et al 
King 
et al 
Casidy 
et al 
Lymphadenopathy 32 14 29 6 39 NR 
Hepatosplenomegaly 70 NR 42 NR 28 43 
 
Feature 
Present
(n=50) 
Surgit singh 
et al(n=16) 
Chandrasekaran 
et al(n=59) 
Ali et 
al 
(n=20) 
Mean age 9.46 8.37 - 9.37 
Children<5 years 10 2(12.5%) 0 1(5%) 
Female:male 2.5:1 7.1 4.9:1 23:1 
Diagnosis at 1 yr 68 66.6 - - 
Nephrotic syndrome 30 31.25 16.9 25 
Fever 94 56 67 16 
Rash 72 50 59 5 
Arthritis 60 50 61 60 
Photosensitivity 52 43.7 10.1 5 
Hemolysis 20 31 0 - 
Feature 
Present
(n=50) 
Surgit singh 
et al(n=16) 
Chandrasekaran 
et al(n=59) 
Ali et 
al 
(n=20) 
Neuropsychiatric 26 31.25 0 5 
Lymphadenopathy 32 18.7 27.1 - 
Oral ulcers 32 25 13.5 - 
Cardiac 8 18.7 1.6 - 
Thrombocytopenia 30 18.7 - - 
Pleuropulmonary 38 12.5 - - 
Raynauds 0 12.5 0 - 
Alopecia 26 12.5 11.8 - 
SUMMARY 
1. SLE can present with protean clinical manifestations. 
2. Diagnosis can be missed if the index of suspicion is not high 
particularly where the typical mucocutaneous features are absent.  
3. Even if the classical criteria are not fulfilled some patients on 
followup turned to be SLE. 
4. 1997 ACR classification criteria are appropriate for use in children. 
5. Slight female preponderance was found in all age groups. 
6. Infantile SLE had onset of disease quite earlier, early renal 
involvement, respiratory involvement and hematological involvement. 
7. Renal involvement in SLE had biopsy of the higher classes (C3, C4, 
C5) and prognosis is poor. Biopsy was done in 70%. Lupus nephritis 
children required induction therapy with methylprednisolone, pulse 
doses of cyclophosphamide, and mycophenolate mofetil. Hence it is 
suggested that all SLE children should undergo renal biopsy earlier. 
8. SLEDAI scoring was high in our children implying disease activity to 
be severe and diagnosis at later stages. 
9. SLICC/ACR DI was low when compared to other studies the reason 
being one year of followup and the possibility that these children may 
develop more organ involvement in future. 
10. ACL/LAC was not done in all cases suggesting that these parameters 
can be taken up separately for future studies. 
11. The mortality rate was 6%.The cause of death being infection in all 
the cases. Both the SLEDAI and SLICC/ACR DI were higher. 
12. Followup of patients can be continued in further prospective studies in 
pediatric SLE. 
13. Adolescent group can also be taken and compared. 
CONCLUSION 
SLE could present with varied clinical manifestations,some could be 
atypical and hence this diagnosis should be considered in case of 
multisystem involvement. Efforts should be directed in diagnosing at earlier 
stage itself for better outcome. SLEDAI and SLICC/ACR DI can be   
incorporated in routine followup to detect mild to moderate and severe flare 
and extent of organ damage.  Renal biopsy can be done in all patients to 
detect earlier silent  involvement, of kidney. Lupus nephritis requires usage 
of methylprednisolone, pulse doses of cyclophosphamide at monthly 
intervals and mycophenolate mofetil. Adolescent group can be taken for 
future prospective studies. 
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